Infliximab for new acute pancreatitis patients in the first 36 hours
Part of Digestive system clinical trials.
This trial tests infliximab (an anti-inflammatory medicine) versus placebo to see if it improves outcomes in adults with newly diagnosed acute pancreatitis. It is designed for treatment to start within 36 hours of hospital admission.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (between 18 and 85 years old)
- You have a new diagnosis of acute pancreatitis confirmed by symptoms, blood tests, and/or urgent imaging
- You can start the study medicine within 36 hours of hospital admission
- You can give consent (or your legal representative can)
- You weigh 200 kg or less
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational medicine called SGC001 given as an injection to people with severe acute pancreatitis, a serious inflammation of the pancreas. The study aims to see if the drug is safe and helpful, and to gather early information on how it works.
This trial tests whether taking a probiotic called Bifidobacterium longum can help people with acute pancreatitis recover better. The study compares the probiotic against a placebo (a pill with no active ingredient) to see if it reduces inflammation and complications.
This trial tests whether taking indomethacin (an anti-inflammatory medicine) early can improve outcomes in people with acute pancreatitis. You might be eligible if your pancreatitis is diagnosed soon and you meet specific lab, imaging, and safety requirements.
This trial studies how “inflammation” in the pancreas changes over time—going from a first or repeated attack to long-term (chronic) pancreatitis. It may help doctors understand what drives progression and identify people at higher risk for chronic disease.
This trial tests a single injection of a new drug called RABI-767, given through a thin tube during an endoscopic ultrasound (EUS), to see if it can help people with severe acute pancreatitis. The drug is meant to reduce inflammation and prevent complications.
This trial tests a supplement called tributyrin (related to butyrate) to see if it can help prevent complications from acute pancreatitis when given early after diagnosis. It is for people having their first episode of pancreatitis, not for those with certain causes or weakened immune systems.
Hear when a new Acute Pancreatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.